(ADMA) ADMA Biologics - Overview
Stock: Immunoglobulin, Hepatitis Antibody, Plasma Collection, Pneumonia Immunoglobulin
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 52.1% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.31 |
| Alpha | -11.98 |
| Character TTM | |
|---|---|
| Beta | 1.103 |
| Beta Downside | 0.944 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.92% |
| CAGR/Max DD | 1.56 |
Description: ADMA ADMA Biologics January 10, 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based biopharmaceutical firm that manufactures and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases, primarily through its IVIG products BIVIGAM and ASCENIV, as well as the hepatitis B post-exposure prophylaxis antibody Nabi-HB. The company also operates its own source-plasma collection network and is advancing a pipeline of plasma-derived therapeutics targeting Streptococcus pneumoniae infections.
For fiscal 2023, ADMA reported net sales of roughly **$140 million**, with BIVIGAM and ASCENIV together accounting for about **70 %** of revenue; cash and cash equivalents stood near **$120 million**, providing a runway of over two years at current burn rates. The pipeline’s lead candidate-a pneumococcal immunoglobulin-has entered Phase II trials, positioning the company to address a market projected to reach **$9 billion** by 2030.
Key economic and sector drivers include a growing prevalence of primary humoral immunodeficiency (estimated at ~ 1 in 5,000 U.S. residents), tightening plasma supply that can lift pricing power for integrated collectors, and favorable reimbursement trends for IVIG therapies under Medicare Part B. Additionally, the broader biotechnology sub-industry is benefiting from a **~ 6 % CAGR** in plasma-derived product demand, driven by an aging population and heightened infection-control focus post-COVID-19.
For a deeper quantitative dive, you may find the analytics on ValueRay useful for evaluating ADMA’s valuation relative to its peers.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 209.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -13.16 > 1.0 |
| NWC/Revenue: 70.85% < 20% (prev 71.39%; Δ -0.54% < -1%) |
| CFO/TA 0.11 > 3% & CFO 65.0m > Net Income 209.4m |
| Net Debt (21.7m) to EBITDA (172.1m): 0.13 < 3 |
| Current Ratio: 7.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (244.7m) vs 12m ago -0.06% < -2% |
| Gross Margin: 54.71% > 18% (prev 0.49%; Δ 5422 % > 0.5%) |
| Asset Turnover: 101.9% > 50% (prev 98.00%; Δ 3.86% > 0%) |
| Interest Coverage Ratio: 19.63 > 6 (EBITDA TTM 172.1m / Interest Expense TTM 8.36m) |
Altman Z'' 3.47
| A: 0.61 (Total Current Assets 402.7m - Total Current Liabilities 56.5m) / Total Assets 568.7m |
| B: -0.37 (Retained Earnings -211.0m / Total Assets 568.7m) |
| C: 0.34 (EBIT TTM 164.1m / Avg Total Assets 479.7m) |
| D: -1.53 (Book Value of Equity -211.0m / Total Liabilities 137.5m) |
| Altman-Z'' Score: 3.47 = A |
Beneish M -0.41
| DSRI: 2.15 (Receivables 137.7m/50.1m, Revenue 488.6m/382.8m) |
| GMI: 0.89 (GM 54.71% / 48.93%) |
| AQI: 3.20 (AQ_t 0.15 / AQ_t-1 0.05) |
| SGI: 1.28 (Revenue 488.6m / 382.8m) |
| TATA: 0.25 (NI 209.4m - CFO 65.0m) / TA 568.7m) |
| Beneish M-Score: -0.41 (Cap -4..+1) = D |
What is the price of ADMA shares?
Over the past week, the price has changed by +2.00%, over one month by -3.24%, over three months by +12.56% and over the past year by +5.04%.
Is ADMA a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ADMA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.7 | 48.4% |
| Analysts Target Price | 25.7 | 48.4% |
| ValueRay Target Price | 25.9 | 49.8% |
ADMA Fundamental Data Overview January 26, 2026
P/E Forward = 28.9855
P/S = 8.1716
P/B = 9.2343
Revenue TTM = 488.6m USD
EBIT TTM = 164.1m USD
EBITDA TTM = 172.1m USD
Long Term Debt = 70.1m USD (from longTermDebt, last quarter)
Short Term Debt = 3.64m USD (from shortTermDebt, last quarter)
Debt = 83.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.01b USD (3.99b + Debt 83.1m - CCE 61.4m)
Interest Coverage Ratio = 19.63 (Ebit TTM 164.1m / Interest Expense TTM 8.36m)
EV/FCF = 98.56x (Enterprise Value 4.01b / FCF TTM 40.7m)
FCF Yield = 1.01% (FCF TTM 40.7m / Enterprise Value 4.01b)
FCF Margin = 8.34% (FCF TTM 40.7m / Revenue TTM 488.6m)
Net Margin = 42.87% (Net Income TTM 209.4m / Revenue TTM 488.6m)
Gross Margin = 54.71% ((Revenue TTM 488.6m - Cost of Revenue TTM 221.3m) / Revenue TTM)
Gross Margin QoQ = 56.34% (prev 55.11%)
Tobins Q-Ratio = 7.06 (Enterprise Value 4.01b / Total Assets 568.7m)
Interest Expense / Debt = 2.02% (Interest Expense 1.68m / Debt 83.1m)
Taxrate = 23.33% (11.1m / 47.5m)
NOPAT = 125.8m (EBIT 164.1m * (1 - 23.33%))
Current Ratio = 7.13 (Total Current Assets 402.7m / Total Current Liabilities 56.5m)
Debt / Equity = 0.19 (Debt 83.1m / totalStockholderEquity, last quarter 431.2m)
Debt / EBITDA = 0.13 (Net Debt 21.7m / EBITDA 172.1m)
Debt / FCF = 0.53 (Net Debt 21.7m / FCF TTM 40.7m)
Total Stockholder Equity = 388.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 43.67% (Net Income 209.4m / Total Assets 568.7m)
RoE = 53.98% (Net Income TTM 209.4m / Total Stockholder Equity 388.0m)
RoCE = 35.83% (EBIT 164.1m / Capital Employed (Equity 388.0m + L.T.Debt 70.1m))
RoIC = 27.32% (NOPAT 125.8m / Invested Capital 460.7m)
WACC = 9.81% (E(3.99b)/V(4.08b) * Re(9.98%) + D(83.1m)/V(4.08b) * Rd(2.02%) * (1-Tc(0.23)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.05%
[DCF Debug] Terminal Value 62.52% ; FCFF base≈56.2m ; Y1≈36.9m ; Y5≈16.8m
Fair Price DCF = 0.96 (EV 251.2m - Net Debt 21.7m = Equity 229.4m / Shares 238.0m; r=9.81% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 79.31 | EPS CAGR: 100.2% | SUE: -3.88 | # QB: 0
Revenue Correlation: 97.27 | Revenue CAGR: 54.31% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.94 | Chg30d=-0.020 | Revisions Net=+0 | Growth EPS=+56.7% | Growth Revenue=+24.3%